State Street’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

State Street’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,205	Closed	-$9K	–	4933
2022 Q3	$9K	Hold	1,205	–	–	﹤0.01%	4897
2022 Q2	$15K	Hold	1,205	–	–	﹤0.01%	4903
2022 Q1	$20K	Buy	1,205 +35	+3%	+$1.12K	﹤0.01%	4884
2021 Q4	$76K	Hold	1,170	–	–	﹤0.01%	4634
2021 Q3	$80K	Hold	1,170	–	–	﹤0.01%	4593
2021 Q2	$82K	Buy	+1,170	New	+$63.3K	﹤0.01%	4395
2020 Q4	–	Sell	-126	Closed	-$8K	–	3919
2020 Q3	$8K	Hold	126	–	–	﹤0.01%	3821
2020 Q2	$16K	Hold	126	–	–	﹤0.01%	3779
2020 Q1	$7K	Hold	126	–	–	﹤0.01%	3736
2019 Q4	$16K	Sell	126 -55	-30%	-$7.45K	﹤0.01%	3772
2019 Q3	$22K	Buy	181 +4	+2%	+$806	﹤0.01%	3760
2019 Q2	$53K	Sell	177 -166	-48%	-$69.2K	﹤0.01%	3717
2019 Q1	$154K	Buy	343 +13	+4%	+$5.69K	﹤0.01%	3598
2018 Q4	$151K	Buy	330 +204	+162%	+$126K	﹤0.01%	3605
2018 Q3	$115K	Hold	126	–	–	﹤0.01%	3640
2018 Q2	$74K	Hold	126	–	–	﹤0.01%	3659
2018 Q1	$82K	Buy	+126	New	+$94.6K	﹤0.01%	3625
2017 Q2	–	Sell	-277	Closed	-$345K	–	3753
2017 Q1	$345K	Buy	+277	New	+$133K	﹤0.01%	3439

Other funds holding HTGM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HWM

HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TWA

TCI Wealth Advisors Tucson, Arizona $1.88B AUM 21.09% 1-Year Est. Return

State Street's HTGM Position: Q4 2022 in Review

State Street sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2022, closing a stake of 1,205 shares — an estimated $9K sold.

State Street first reported a position in HTGM in Q1 2017 and held it in 18 quarters. The position peaked at $345K in Q1 2017. 10 funds tracked by Wall St. Rank hold HTGM as of Q4 2022.

State Street reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
State Street sold 1,205 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2022, an estimated $9K.
State Street first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2017 and held it in 18 quarters.
State Street's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $345K in Q1 2017.
10 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2022.

Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.